Larose Jean-Christophe, Wang Han Ting, Rakovich George
Division of Critical Care, Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.
Division of Thoracic Surgery, Department of Surgery, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada.
J Thorac Dis. 2023 Jul 31;15(7):3860-3869. doi: 10.21037/jtd-22-1590. Epub 2023 Jul 20.
Necrotizing pneumonia and lung gangrene represent a continuum of severe lung infection. Traditionally, severe cases have been referred for surgical debridement. However, this has been linked to high mortality. Some groups have published encouraging results using a conservative medical approach. Unfortunately, lack of a standardized definition of necrotizing pneumonia has precluded meaningful comparison between medical and surgical approach in severe cases. Our objective was to describe the outcome of a cohort of severe necrotizing pneumonia treated with optimal medical management.
We conducted an observational retrospective study by reviewing charts and radiology records of patients hospitalized between 2006-2019 in a tertiary center. We included all patients with severe necrotizing infection, defined as a necrotizing cavity involving at least 50% of a lobe, or smaller multilobar cavities. We made no distinction between necrotizing pneumonia and gangrene as there are no standardized criteria.
A total of 50 consecutive patients were included. On imaging, 42% had multilobar cavities and mean diameter of the largest cavity in each case was 5.9 cm. 50% required mechanical ventilation (median duration 12 days) and 44% needed vasopressors. Four patients (8%) had decortication surgery, while none underwent lung resection. Four patients (8%) died. The extent of infiltrates and number of cavities were not associated with mortality but the extent of infiltrates was associated with risk of intubation (P=0.004).
We presented one of the largest series of medically-treated severe necrotizing lung infections in the pre-coronavirus disease-2019 (COVID-19) era. The overwhelming majority of patients recovered with optimal medical management alone. Our results strongly support avoiding pulmonary resection in patients with severe necrotizing bacterial lung infections.
坏死性肺炎和肺坏疽是严重肺部感染的连续过程。传统上,严重病例会接受外科清创术。然而,这与高死亡率相关。一些研究团队发表了采用保守药物治疗方法取得的令人鼓舞的结果。不幸的是,坏死性肺炎缺乏标准化定义,这使得在严重病例中无法对药物治疗和手术治疗方法进行有意义的比较。我们的目的是描述一组采用最佳药物治疗的严重坏死性肺炎患者的治疗结果。
我们通过回顾2006年至2019年在一家三级中心住院患者的病历和放射学记录进行了一项观察性回顾性研究。我们纳入了所有患有严重坏死性感染的患者,定义为坏死性空洞累及至少一个肺叶的50%,或较小的多叶空洞。由于没有标准化标准,我们未区分坏死性肺炎和坏疽。
共纳入50例连续患者。影像学检查显示,42%的患者有多叶空洞,每个病例中最大空洞的平均直径为5.9厘米。50%的患者需要机械通气(中位持续时间为12天),44%的患者需要血管加压药。4例患者(8%)接受了剥脱术,无人接受肺切除术。4例患者(8%)死亡。浸润范围和空洞数量与死亡率无关,但浸润范围与插管风险相关(P=0.004)。
我们呈现了2019冠状病毒病(COVID-19)大流行之前最大的一组接受药物治疗的严重坏死性肺部感染病例。绝大多数患者仅通过最佳药物治疗即可康复。我们的结果有力地支持避免对严重坏死性细菌性肺部感染患者进行肺切除术。